Quantus

Cellromax Science

A471820 · KOSDAQ
₩4,070+8.24%
2026-08-03 close
Loading chart…
Close
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
No

No active signal.

Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Annual dividend

Split-adjusted annual DPS history and available grade axes

Annual dividend per share chart2025: 300원300원2025
Annual dividend (per share · split-adjusted) · as of 2025
Consistency
D
Yield
A+

Paid 1 consecutive years · Raised 0 consecutive years · Yield 7.37% (based on 2025 payment of 300원)

Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 16.85
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
16.85
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
-5.04%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROAPass
  • Positive OCFPass
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
25.4%
Interest coverage
145.7x
Return on equity (ROE)
8.6%

Operating margin −5pp

Tolerable
Interest coverageBase 145.7x adverse case 117.1x
Return on equity (ROE)Base 8.6% adverse case 9.8%

Revenue −15%

Tolerable
Interest coverageBase 145.7x adverse case 123.9x
Return on equity (ROE)Base 8.6% adverse case 10.4%

Interest rate +2pp

Tolerable
Interest coverageBase 145.7x adverse case 42.6x
Return on equity (ROE)Base 8.6% adverse case 12.1%

Interest coverage limit

Current margin 25.3pp

Interest coverage limit at an operating margin of 0.2%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-06-29

Suppliers disclosed by the company in its 2026-06-29 annual report.

Suppliers without disclosed amount

노바렉스Price comovement r=0.05 (1 year)네이처텍325알피바이오Price comovement r=0.14 (1 year)경방신약리스앙쥬90팜텍코리아옥수

Financials at a glance

Cellromax Science's latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 서정민71.45%2026-04-07 · 증감 +1.87%p
  • 박민정10.21%2026-01-27 · 증감 +0.42%p

Connections

AI-extracted related companies · for reference

Customers
쿠팡네이버올리브영
🔗 See in the full market map →

Recent filings

Cellromax Science's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy